Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 4/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 9/20 | 0.33 |
| ▸ | FABP3 | P05413 | 1/20 | 0.32 |
| ▸ | FABP4 | P15090 | 1/20 | 0.32 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.32 |
| ▸ | MOGAT2 | Q3SYC2 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20351583 | 0.81 | SCN9A (0.34) | SCN9AMOGAT2 | |
| SCHEMBL20207598 | 0.71 | SCN9A (0.44) | SCN9AMOGAT2 | |
| SCHEMBL22548331 | 0.68 | HTR2C (0.36) | SCN9AADRA2AADRA2BADRA2C | |
| SCHEMBL20373902 | 0.67 | SCN9A (0.43) | SCN9A | |
| SCHEMBL18374371 | 0.65 | SCN9A (0.42) | SCN9A | |
| SCHEMBL21350429 | 0.65 | SCN9A (0.40) | SCN9AMOGAT2 | |
| Hydrochloric Acid SCHEMBL20191182 | 0.65 | SCN9A (0.41) | SCN9A | |
| Hydrochloric Acid SCHEMBL20191183 | 0.65 | SCN9A (0.41) | SCN9A | |
| SCHEMBL20351723 | 0.64 | SCN9A (0.43) | SCN9AFABP3FABP4FABP5 | |
| SCHEMBL20201944 | 0.64 | SCN9A (0.43) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10570098-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2020-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10570098-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | DUT, TYMP, DPYD | SCN9A 4663/4885TRPV1 4643/4885FABP3 2939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.